

PRELIMINARY PROGRAM

BEST OF ASCO®

OFFICIALLY LICENSED

August 29 - 30, 2024,
Almaty, Kazakhstan

29/08/2024 - DAY 1	
Opening Ceremony	09:30 – 10:00
Welcome speech Dr. Marat Shoranov MD, PhD, Chairman of the Board, Rector, “Kazakh National Medical University named after S.D. Asfendiyarov» Kazakhstan	09:30 – 09:35
Welcome speech Dr. Eric Winer MD, FASCO ASCO President, 2022-2023 Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven USA	09:35 – 09:40
Welcome speech Dr. Don S. Dizon MD, Director of Pelvic Malignancies Program and Hematology - Oncology Outpatient Clinics USA	09:40– 09:45
Welcome speech Dr. Otis Brawley Clinical Researcher to the American Eurasian Cancer Alliance, Senior VP of John Hopkins University USA	09:45 – 09:50
Welcome speech Dr. Dilyara Kaidarova MD, PhD, Professor, Academician of National Academy of Sciences Republic of Kazakhstan CEO KazIOR, President of Oncologists and Radiologists Association Republic of Kazakhstan Kazakhstan	09:50 – 10:00
Lung Cancer—Small Cell/Other Thoracic Cancers Chairs: Ilya Tsimafeyeu/ Aliya Turesheva	10:00 – 11:00
Ilya Tsimafeyeu Director of the Bureau of Cancer Research (USA), member of the International Committee of the American Society of Clinical Oncology (ASCO, USA), lecturer at the College of the European School of Oncology (Italy), member of the editorial board of the scientific journal Kidney Cancer, Scientific director and coordinator of consultations of Science & Technology in Oncology USA ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)	10:00 – 10:30

Rabiga Kadyrbaeva PhD candidate, medical oncologist of chemotherapy center KazIOR Kazakhstan BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A) as first-line treatment (TX) for advanced pleural mesothelioma (PM) —Results from the ETOP 13-18 trial	10:30 – 10:50
Discussion	10:50 – 11:00
Coffee break	11:00 – 11:30
Lung Cancer—Non-Small Cell Chairs: Ilya Tsimafeyev/ Aliya Turesheva	11:30 – 12:40
Ahmed Omar Al Lehebi Consultant, medical oncologist of king Faisal Hospital & Research Center of Jeddah, Chairman of scientific committee of medical oncology, Program director of the medical oncology fellowship program at KFSHRC- Jeddah Saudi Arabia Lorlatinib vs crizotinib in treatment of patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study	11:30 – 12:00
Natia Jokhadze MD, Chief of Clinical Oncology Department at American Hospital in Tbilisi Georgia Osimertinib (osi) after radical chemoradiotherapy in patients with unresectable stage III (stg) EGFRm-mutated NSCLC: primary results from the phase 3 LAURA trial.	12:00 – 12:30
Discussion	12:30 – 12:40
Lunch	12:40 – 13:40
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Chairs: Indira Omarova/ Dauranbek Arybzhhanov	13:40 – 14:40
Kaldygul Smagulova Candidate of Medical Sciences, Head of Chemotherapy Day Hospital KazIOR Kazakhstan Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial)	13:40 – 14:00
Timur Mitin – Online Professor of Radiation Oncology of Oregon Health and Science University, Radiation oncologist of OHSU Knight Cancer Institute of Portland USA NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)	14:00 – 14:30
Discussion	14:30 – 14:40
Gastrointestinal Cancer - Colorectal and Anal Chairs: Indira Omarova/ Dauranbek Arybzhhanov	14:40 – 15:50

Purevbaatar Bat-Ireedui Interventional surgeon, employee of the Yonsei Research Institute of Republic of Korea (Yonsei University, Korea), Head of Cancer Treatment Department Mongolia Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial	14:40 – 15:10
Dos Sarbasov PhD, General Director of the National Laboratory Astana, Professor of the School of Natural Social and Humanitarian Sciences of Nazarbayev University Kazakhstan Circulating tumor DNA analysis guiding adjuvant therapy in stage II of colon cancer: overall survival and updated 5-year results from the randomized DYNAMIC trial	15:10 – 15:40
Discussion	15:40 – 15:50
Coffee break	15:50 – 16:20